KR101290795B1 - Manufacturing methods of fermentation bellflower increased aneffective ingredient - Google Patents
Manufacturing methods of fermentation bellflower increased aneffective ingredient Download PDFInfo
- Publication number
- KR101290795B1 KR101290795B1 KR1020110071878A KR20110071878A KR101290795B1 KR 101290795 B1 KR101290795 B1 KR 101290795B1 KR 1020110071878 A KR1020110071878 A KR 1020110071878A KR 20110071878 A KR20110071878 A KR 20110071878A KR 101290795 B1 KR101290795 B1 KR 101290795B1
- Authority
- KR
- South Korea
- Prior art keywords
- bellflower
- fermented
- yeast
- saccharomyces
- platicodin
- Prior art date
Links
- 241000332371 Abutilon x hybridum Species 0.000 title claims abstract description 154
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 39
- 230000001965 increasing effect Effects 0.000 title claims abstract description 36
- 238000000855 fermentation Methods 0.000 title claims description 14
- 230000004151 fermentation Effects 0.000 title claims description 14
- 239000004615 ingredient Substances 0.000 title 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 65
- 229920001353 Dextrin Polymers 0.000 claims abstract description 24
- 239000004375 Dextrin Substances 0.000 claims abstract description 24
- 235000019425 dextrin Nutrition 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 56
- 241000235070 Saccharomyces Species 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 19
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 230000000845 anti-microbial effect Effects 0.000 claims description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 claims description 4
- 241000877401 Saccharomyces ellipsoideus Species 0.000 claims description 4
- 241001123227 Saccharomyces pastorianus Species 0.000 claims description 4
- 241000235017 Zygosaccharomyces Species 0.000 claims description 4
- 241000235033 Zygosaccharomyces rouxii Species 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 244000286779 Hansenula anomala Species 0.000 claims description 3
- 235000014683 Hansenula anomala Nutrition 0.000 claims description 3
- QLRRUWXMMVXORS-UHFFFAOYSA-N Augustine Natural products C12=CC=3OCOC=3C=C2CN2C3CC(OC)C4OC4C31CC2 QLRRUWXMMVXORS-UHFFFAOYSA-N 0.000 claims description 2
- 241001237431 Anomala Species 0.000 claims 1
- 235000018338 Hansenula anomala anomala Nutrition 0.000 claims 1
- 244000253773 Hansenula anomala anomala Species 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 235000019658 bitter taste Nutrition 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 8
- 238000012258 culturing Methods 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 206010013911 Dysgeusia Diseases 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229930182490 saponin Natural products 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 description 5
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 208000014181 Bronchial disease Diseases 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 4
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- -1 analgesic Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- GWBIYORWNUYYMZ-UHFFFAOYSA-N platycodin D Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(O)C(O)C1OC9OCC(O)C(OC%10OCC(O)(CO)C%10O)C9O GWBIYORWNUYYMZ-UHFFFAOYSA-N 0.000 description 2
- CYBWUNOAQPMRBA-NDTOZIJESA-N platycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CYBWUNOAQPMRBA-NDTOZIJESA-N 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000007218 ym medium Substances 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- KLYCPFXDDDMZNQ-UHFFFAOYSA-N Benzyne Chemical compound C1=CC#CC=C1 KLYCPFXDDDMZNQ-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- YDQIRODFTJGGMP-UHFFFAOYSA-N Prosapogenin Chemical compound C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC34)C)(CO)C1=CCC2C3(C)CC(O)C(O)C4(C)C(=O)OC1OC(CO)C(O)C(O)C1O YDQIRODFTJGGMP-UHFFFAOYSA-N 0.000 description 1
- 206010058824 Pulmonary necrosis Diseases 0.000 description 1
- 241001115903 Raphus cucullatus Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000226211 Salminus brasiliensis Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000138620 Talinum patens Species 0.000 description 1
- ZNFRITHWVZXJRK-UHFFFAOYSA-N Vitalboside A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O ZNFRITHWVZXJRK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- VTXFLUJNMHWAAT-UHFFFAOYSA-N alternoside VII Natural products CC1(C)CC(O)C2(CO)C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(C(O)C(OC7OC(CO)C(O)C(O)C7O)C6O)C(=O)O)C(C)(C)C5CCC34C)C2C1 VTXFLUJNMHWAAT-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229930188557 apratoxin Natural products 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 241000385735 bacterium K Species 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- OILHVNROWDFZDW-UHFFFAOYSA-N prosapogenin Natural products CC1(C)CCC2(C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C=O)C5CCC34C)C2C1)C(=O)O OILHVNROWDFZDW-UHFFFAOYSA-N 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- IAGSHEHQJJTLLR-UHFFFAOYSA-N sapindoside B Natural products OC1C(C)OC(OC2C(OCC(O)C2O)OC2C(C3C(C4C(C5(CCC6(CCC(C)(C)CC6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)C(O)C1OC1OCC(O)C(O)C1O IAGSHEHQJJTLLR-UHFFFAOYSA-N 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 125000003523 triterpene group Chemical group 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
본 발명은 유효성분이 증가된 발효 도라지 제조방법에 관한 것으로, 더욱 구체적으로 도라지를 효모로 배양하는 단계 또는 누룩으로 발효시키는 단계를 포함하는 플라티코딘 D의 함량이 증가된 발효 도라지 제조방법에 관한 것이다.
본 발명에 따르면 탁주 제조공정을 적용시킨 본 발명의 발효 도라지 제조방법을 이용하여, 플라티코딘 D의 함량이 증가된 발효 도라지를 제조할 수 있다. 본 발명에서는, 분쇄된 도라지를 누룩에서 분리한 효모로 배양하는 경우, 누룩으로 발효시키는 경우 또는 효모로 배양한 후 누룩으로 발효시키는 경우 일반 도라지 추출물에 비해 플라티코딘 D의 함량이 유의적으로 증가되는 것을 확인하였으며, 도라지 발효물을 싸이클로 덱스트린 또는 덱스트린으로 포접시키는 경우 도라지 특유의 쓴 맛을 제거할 수 있었다. 따라서 본 발명의 제조방법을 통해 제조된 플라티코딘 D의 함량이 증가된 발효 도라지 조성물은 기능성 식품 조성물 또는 약제학적 조성물에 유용하게 사용될 수 있을 것으로 사료된다.The present invention relates to a method for producing fermented bellflower with an increased active ingredient, and more particularly, to a method for producing fermented bellflower with an increased content of Platicodin D, including culturing the bellflower with yeast or fermenting it with yeast. .
According to the present invention, by using the fermented bellflower production method of the present invention to which the Takju production process is applied, it is possible to produce a fermented bellflower with an increased content of Platicodin D. In the present invention, when the cultivated pulverized bellflower is cultured with yeast isolated from yeast, fermented with yeast or fermented with yeast after cultivating with yeast, the content of Platicodin D is significantly increased as compared to general bellflower extract. When the bellflower fermented product was included in the cycle with dextrin or dextrin, the bitter taste peculiar to the bellflower could be removed. Therefore, the fermented bellflower composition with increased content of Platicodin D prepared through the preparation method of the present invention may be usefully used in functional food compositions or pharmaceutical compositions.
Description
본 발명은 유효성분이 증가된 발효 도라지 제조방법에 관한 것으로, 더욱 구체적으로 도라지를 효모로 배양하는 단계 또는 누룩으로 발효시키는 단계를 포함하는 플라티코딘 D의 함량이 증가된 발효 도라지 제조방법에 관한 것이다.
The present invention relates to a method for producing fermented bellflower with an increased active ingredient, and more particularly, to a method for producing fermented bellflower with an increased content of Platicodin D, including culturing the bellflower with yeast or fermenting it with yeast. .
도라지는 한의학에서는 길경(桔梗)이라고 하며, 초롱과에 속하는 다년생초로서 한국을 비롯한 중국, 일본 등지에 자생하며, 배농, 거담, 기관지염, 천식 등의 호흡기계 질환에 사용되어온 생약재로서 도라지가 배합되어 있는 한방처방 수는 동의보감에 273건, 방약합편에 49건이 수록되어 있을 정도로 다양한 약리작용을 가지고 있다. 도라지의 주요 약리성분은 트리테르페노이드(triterpenoid)계 사포닌(saponin)으로 동물실험에서 이 물질은 진해, 거담작용, 중추신경억제작용(진정, 진통, 해열효과), 급만성염증에 대한 항염증 작용, 항궤양 및 위액분비억제작용, 혈관을 확장하여 혈압을 낮추는 항콜린작용, 혈당강하작용, 콜레스테롤대사 개선작용 등이 있을 것으로 밝혀졌다. 이외에 도라지의 열수 및 에탄올 추출물은 곰팡이의 아프라톡신을 억제하며, 이눌린 분획은 식균작용과 고형암 및 복수암에 대한 강력한 항종양 효능이 있고, 40% 도라지엑기스는 알코올흡수 억제작용이 규명된 바 있다.The bellflower is called Gilgyeong (桔梗) in Oriental medicine, and it is a perennial herb belonging to the lantern family. It grows in Korea, China, Japan, etc. The number of oriental prescriptions has a variety of pharmacological effects, including 273 in consent and one in 49. The major pharmacological component of bellflower is triterpenoid-based saponin (saponin). In animal experiments, it is anti-inflammatory for antitussive, expectorant, central nervous system (sedative, analgesic, antipyretic) and acute inflammation. Action, anti-ulcer and gastric secretion suppression, blood vessels dilate blood pressure lowering anticholinergic, hypoglycemic action, cholesterol metabolism improvement, etc. have been found. In addition, the hot water and ethanol extract of bellflower inhibit the apratoxin of the fungus, and the inulin fraction has potent antitumor effect against phagocytosis and solid and ascites cancers, and 40% bellflower extract has been shown to inhibit alcohol absorption. .
도라지는 기침과 해소를 위해 생도라지를 구워먹거나 건 도라지를 끓여 먹는 등의 형태로 활용되고 있다. 또한 최근 연구에서 도라지가 약리 및 항균효과가 있다는 보고가 있으며 이를 입증하고자 무발효 도라지 및 발효도라지에 대한 항균활성을 알아보고자 하였다. 기관지 질환은 주로 감기나 대기 오염, 흡연, 건조등의 원인이 되어 기관지내의 점막세포가 약해 졌을 때 병원성 세균에 의한 2차 감염이 진행되어 염증을 유발하게 되어 이들 질환의 진행이 지속되면 천식과 폐렴, 폐결핵으로 유도되는 것으로 알려지고 있다. 특히 Klebsiella 폐렴은 전체폐렴의 0.5 ~ 5.0%, 그리고 사회감염성 폐렴의 6 ~ 8.6%를 차지하고 있고, 당뇨병이나 만성폐질환을 가지고 있는 40대의 남자에게서 잘 발생하며, 특히 만성 알콜남용은 클렙시엘라 폐렴의 위험인자군으로 널리 알려져 있다. 원인균은 Klebsiella pneumoniae로서 호기성의 그람 음성 간균이며 대식작용으로부터 균자신을 보호할 수 있는 두꺼운 막낭에 둘러싸여있어 치료하기가 힘든 특징을 있다. 임상증상으로는 고열, 기침, 객혈, Curreant - Jelly형의 객담 배출을 동반한 매우 빨리 진행하는 급성호흡기 증상이 대부분이다. 진단은 객담 및 혈액배양검사에서 K. pneumoniae균의 동정으로 할 수 있다. Klebsiella 폐렴은 드물지만 매우 빠르고 광범위한 폐괴저를 유발하는 경우에 있어서 내과적인 치료만으로는 급성호흡부전, 패혈증, 다발성 장기부전 등의 매우 치명적인 결과를 가져올 수 있으며, 급성기 폐렴상태임도 불구하고 조기에 적극적인 외과적 치료를 병행하는 것이 환자의 생존에 필수적인 방법으로 되어있다.Bellflower is used in the form of grilling raw bellflower or boiling dried bellflower for coughing and relief. In addition, a recent study reported that the bellflower has pharmacological and antimicrobial effects, and to verify this, the antimicrobial activity against fermented bellflower and fermented bellflower was investigated. Bronchial diseases are mainly caused by colds, air pollution, smoking, and drying, and when mucosal cells in the bronchus weaken, secondary infections by pathogenic bacteria progress, causing inflammation, and asthma and pneumonia persist. It is known to lead to pulmonary tuberculosis. In particular, Klebsiella pneumonia accounts for 0.5 to 5.0% of all pneumonia and 6 to 8.6% of socially-infectious pneumonia, and occurs in men in their 40s with diabetes or chronic lung disease, especially chronic alcohol abuse of Klebsiella pneumonia. It is widely known as a risk factor group. The causative agent is Klebsiella As a pneumoniae, it is an aerobic Gram-negative bacillus and is difficult to treat because it is surrounded by a thick membrane capsule that can protect itself from macrophages. Most of the clinical symptoms are very fast-paced acute respiratory symptoms with high fever, cough, hemoptysis, and sputum discharge of Curreant-Jelly type. K diagnosis in sputum and blood cultures. It is possible to identify pneumoniae bacteria. Klebsiella Pneumonia is rare, but in the case of very fast and widespread pulmonary necrosis, medical treatment alone can have very fatal consequences such as acute respiratory failure, sepsis and multiple organ failure. Parallel is an essential method for patient survival.
생약학(한대석, 1998)을 보면, 여러 효능을 가지고 있는 도라지 추출물의 주성분은 플라티코딘 D(Platycodin D) 이며, 이에 결합한 당은 오탄당인 D-apiose로서 플라티코딘(Platycodins)의 생리작용과 밀접한 관계에 있는 것으로 보고 있다. 이와 같이 사포닌 배당체의 완전 또는 부분 deglycosyldation은 부작용의 완화와 함께 새로운 생활성체로의 검색에 대한 접근으로 이용될 수 있다.According to the herbal medicine (Han Dae-seok, 1998), the main component of the extract of Platycodin D, which has several effects, is Platycodin D. I see it as a relationship. As such, complete or partial deglycosyldation of saponin glycosides can be used as an approach to the search for new biomes with alleviation of side effects.
사람이나 동물에서의 사포닌의 deglycosyldation은 완전히 가수분해된 자유 prosapogenin으로 배출되기 위해서는 위산이나 장내 세균의 deglycosidase에 의해 매개되어야만 한다. 화학적 가수분해와 달리 효소에 의한 배당 사슬의 부분적 가수분해는 glycosidic bond를 분리하는데 도움을 주고, 새로운 산출물을 생성할 수 있다. 이러한 천연 사포닌의 구조적 변형과 기능적 개선에 좋은 수단이 될 수 있다. 길경의 사포닌인 플라티코딘(Plytycodin)은 알려진 약리학적 효능에도 불구하고 특이한 아린 맛과 쓴 맛을 가지고 있다.Deglycosyldation of saponins in humans or animals must be mediated by gastric acid or intestinal bacteria deglycosidase to be released into fully hydrolyzed free prosapogenin. Unlike chemical hydrolysis, partial hydrolysis of glycoside chains by enzymes helps to separate glycosidic bonds and produce new outputs. It can be a good means for structural modification and functional improvement of such natural saponins. Plytycodin, a saponin of Gilt, has a distinctive arine and bitter taste despite its known pharmacological effects.
한편, 누룩은 우리나라의 전통주인 탁주 및 약주의 양조에 있어서 쌀 등의 전분질원료를 분해하는 amylase를 비롯한 각종 가수분해효소를 공급하고 효모를 비롯한 발효관련 미생물의 접종원으로서 중요한 역할을 하고 있다.On the other hand, Nuruk supplies various hydrolytic enzymes including amylase to decompose starch raw materials such as rice in the brewing of traditional liquor, Takju and Yakju, and plays an important role as inoculator of fermentation-related microorganisms including yeast.
일반적으로 탁주는 증자(蒸煮)시킨 전분질 원료에 곰팡이류(種麴)를 인위적으로 번식시킨 입국(粒麴)을 사용하여 전분질을 당화시키고 효모를 투여하여 발효시킨 밑술(酒母)을 제조하고, 제조된 밑술에 물, 입국을 투여하여 1단 담금시킨 후, 다시 물과 증자된 쌀을 투여하여 2단 담금 시킨 후 숙성시켜 고운 체로 걸러내면 탁주 원액이 제조된다.In general, Takju was prepared by saponifying starch by fermenting starch using artificially propagated molds on the increased starch raw material and producing yeast fermented by administering yeast. Takju undiluted solution is prepared by immersing one stage by administering water and immigration to the lower liquor, then immersing with two stages by administering water and steamed rice.
이에, 본 발명자들은 상기 종래기술들의 문제점들을 극복하기 위하여 예의 연구 노력한 결과, 기존의 탁주 제조방법인 고슬밥(찐쌀)에 누룩을 넣고 발효하는 공정을 이용하여 도라지를 발효시키는 경우, 도라지의 유효성분인 플라티코딘 D의 함량을 효과적으로 증가시킬 수 있음을 확인하고, 본 발명을 완성하게 되었다.
Therefore, the present inventors have made diligent research efforts to overcome the problems of the prior art, when fermenting the bellflower by using the process of fermenting the koji in goosebap (steamed rice), which is a conventional Takju manufacturing method, the active ingredient of bellflower It was confirmed that it can effectively increase the content of phosphorus Platicodin D, and completed the present invention.
따라서, 본 발명의 주된 목적은 플라티코딘 D의 함량을 증가시킨 발효 도라지 제조방법을 제공하는데 있다.Therefore, the main object of the present invention is to provide a method for producing fermented bellflower with increased content of Platicodin D.
본 발명의 다른 목적은 상기 제조방법을 이용한 플라티코딘 D의 함량이 증가되고 도라지 특유의 고미를 감소시킨 발효 도라지 조성물을 제공하는데 있다.
It is another object of the present invention to provide a fermented bellflower composition in which the content of Platicodin D using the preparation method is increased and the bellflower characteristic is reduced.
본 발명의 한 양태에 따르면, 본 발명은 하기의 단계를 포함하는 것을 특징으로 하는 플라티코딘 D의 함량이 증가된 발효 도라지 제조방법을 제공한다:According to one aspect of the present invention, the present invention provides a method for producing a fermented bellflower with an increased content of Platicodin D, comprising the following steps:
a) 도라지를 분쇄하는 단계;a) grinding the bellflower;
b) 분쇄된 도라지를 멸균시키는 단계;b) sterilizing the ground bellflower;
c) 멸균된 도라지를 누룩으로 발효시키는 단계;c) fermenting the sterilized bellflower with yeast;
d) 발효 완료된 도라지를 여과 및 농축시키는 단계; 및d) filtering and concentrating the fermented bellflower; And
e) 동결건조하여 분말화시키는 단계.e) lyophilization to powder.
본 발명의 제조방법에 있어서, 상기 c) 단계에서 멸균된 도라지 1 kg 당 5 내지 30%의 누룩, 바람직하게는 50 내지 100 g의 누룩을 넣고, 25 내지 35 ℃에서 2 내지 4 일간 배양하는 것을 특징으로 한다. 여기서, 누룩이란 술을 만드는 효소를 갖는 곰팡이를 곡류에 번식시킨 것을 의미하며, 본 발명의 실시예에서는 우리나리의 전통주인 탁주 및 약주의 양조에 쓰이는 누룩을 분쇄하여 사용하였다.In the preparation method of the present invention, 5 to 30% of yeast, preferably 50 to 100 g of yeast per 1 kg of the sterilized bellflower in step c), and incubated for 2 to 4 days at 25 to 35 ° C It features. Here, Nuruk means that the fungus having an alcohol-making fungus is propagated in cereals, and in the embodiment of the present invention, the Nuruk used for brewing Takju and Yakju, which are traditional liquors of Uri, is used by grinding.
본 발명의 제조방법에 있어서, 상기 c) 단계 이전에 멸균된 도라지를 효모로 배양시키는 단계를 더 포함하는 것을 특징으로 한다.In the production method of the present invention, further comprising the step of culturing the sterilized bellflower before yeast step c).
상기 배양에 이용되는 효모는 누룩에서 분리한 것으로, 사카로미세스 세레비시아(Saccharomyces cerevisiae), 사카로미세스 엘립소이데우스(Saccharomyces ellipsoideus), 사카로미세스 코리아누스(Saccharomyces coreanus), 사카로미세스 카를스베르겐시스(Saccharomyces carlsbergensis), 지고사카로미세스 마조르(Zygosaccharomyces major), 사카로미세스 락틱(Saccharomyces lactics), 사카로미세스 록시이(Saccharomyces rouxii), 및 한세뉼라 아노말라(Hansenula anomala)로 구성된 군에서 선택되는 것을 특징으로 한다.Yeast used for the culture is isolated from yeast, Saccharomyces cerevisiae , Saccharomyces ellipsoideus ( Saccharomyces) ellipsoideus ), Saccharomyces coreanus ), Saccharomyces carlsbergensis ), Zygosaccharomyces major ), Saccharomyces lactics ), Saccharomyces rouxii ), and Hansenula anomala .
본 발명의 구체적인 실시예에서는 상기 기재된 제조방법 즉, 탁주 제조공정을 적용시켜 발효 도라지를 제조하는 경우, 플라티코딘 D의 함량이 증가된 것을 확인하였다. 보다 구체적으로, 분쇄시킨 도라지를 누룩으로 발효 시키거나, 분쇄시킨 도라지를 효모로 배양시킨 후 누룩으로 발효시키는 경우 대조군(도라지 추출물)에 비해 각각 플라티코딘 D의 함량이 2배 이상, 4배 이상 증가되었다 (실시예 2 및 도 2 참조).In the specific example of the present invention, when the fermented bellflower was prepared by applying the above-described manufacturing method, that is, the preparation process of Takju, it was confirmed that the content of Platicodin D was increased. More specifically, when the pulverized bellflower is fermented with Nuruk, or when the pulverized Bellflower is incubated with yeast and fermented with Nuruk, the content of Platicodin D is two or more times and four times or more, respectively, compared to the control (flower bellflower). Increased (see Example 2 and FIG. 2).
본 발명의 제조방법에 있어서, 상기 d) 단계의 농축 수행시, 포접시키는 단계를 더 포함하는 것을 특징으로 한다.In the production method of the present invention, the concentration of step d), characterized in that it further comprises the step of inclusion.
상기 포접은 알파, 베타, 감마 싸이클로 덱스트린 및 덱스트린으로 구성된 군에서 선택된 덱스트린으로 포접시키는 것을 특징으로 하며, 보다 구체적으로 상기 포접은 발효 도라지 고형분 대비 1 내지 40 w/w%의 덱스트린을 첨가하고, 0.5 내지 5 시간 동안 50 내지 500 rpm으로 교반시켜 수행하는 것을 특징으로 한다.The inclusion is characterized in that the inclusion of the dextrin selected from the group consisting of alpha, beta, gamma cyclodextrin and dextrin, more specifically the inclusion is added 1 to 40 w / w% of dextrin relative to the fermented bellflower solids, 0.5 It is characterized by performing by stirring at 50 to 500 rpm for 5 hours.
본 발명의 구체적인 실시예를 통해 분쇄시킨 도라지를 효모배양 후 누룩발효 시킨 발효 도라지를 여러 덱스트린으로 포접시킨 후, 포접시킨 시료의 고미평가를 수행한 결과, 알파 또는 감마 싸이클로 덱스트린으로 포접시킨 경우 고미제거율이 80% 이상으로 측정됨을 확인하였다 (실시예 3 및 도 3 참조).
After cultivating the bellflower pulverized by yeast culture in a specific embodiment of the present invention, the fermented bellflower fermented with yeast fermented with various dextrins, and then subjected to high-evaluation of the inclusion sample, when the inclusion of alpha or gamma cyclodextrin high removal rate It was confirmed that this is measured at 80% or more (see Example 3 and Figure 3).
본 발명의 다른 양태에 따르면, 본 발명은 하기의 단계를 포함하는 것을 특징으로 하는 플라티코딘 D의 함량이 증가된 발효 도라지 제조방법을 제공한다:According to another aspect of the present invention, the present invention provides a method for preparing fermented bellflower with an increased content of Platicodin D, comprising the following steps:
a) 도라지를 분쇄하는 단계;a) grinding the bellflower;
b) 분쇄된 도라지를 멸균시키는 단계;b) sterilizing the ground bellflower;
c) 멸균된 도라지를 효모로 배양시키는 단계;c) incubating the sterile bellflower with yeast;
d) 발효 완료된 도라지를 여과 및 농축시키는 단계; 및d) filtering and concentrating the fermented bellflower; And
e) 동결건조하여 분말화시키는 단계.e) lyophilization to powder.
본 발명의 제조방법에 있어서, 상기 c) 단계에서 멸균된 도라지 1 kg 당 효모종균액을 3 내지 7% 농도로 접종, 바람직하게는 150 내지 300 mL로 접종하여, 25 내지 35 ℃에서 2 내지 4 일간 배양하는 것을 특징으로 한다.In the production method of the present invention, inoculated at a concentration of 3 to 7% of the yeast seed solution per kg of the bellflower sterilized in step c), preferably inoculated at 150 to 300 mL, 2 to 4 at 25 to 35 ℃ It is characterized by culturing daily.
본 발명의 제조방법에 있어서, 상기 d) 단계의 농축 수행시, 포접시키는 단계를 더 포함하는 것을 특징으로 한다. 상기 포접은 알파, 베타, 감마 싸이클로 덱스트린 및 덱스트린으로 구성된 군에서 선택된 덱스트린으로 포접시키는 것을 특징으로 하며, 보다 구체적으로 상기 포접은 발효 도라지 고형분 대비 1 내지 40 w/w%의 덱스트린을 첨가하고, 0.5 내지 5 시간 동안 50 내지 500 rpm으로 교반시켜 수행하는 것을 특징으로 한다.In the production method of the present invention, the concentration of step d), characterized in that it further comprises the step of inclusion. The inclusion is characterized in that the inclusion of the dextrin selected from the group consisting of alpha, beta, gamma cyclodextrin and dextrin, more specifically the inclusion is added 1 to 40 w / w% of dextrin relative to the fermented bellflower solids, 0.5 It is characterized by performing by stirring at 50 to 500 rpm for 5 hours.
상기 배양에 이용되는 효모는 누룩에서 분리한 것으로, 사카로미세스 세레비시아(Saccharomyces cerevisiae), 사카로미세스 엘립소이데우스(Saccharomyces ellipsoideus), 사카로미세스 코리아누스(Saccharomyces coreanus), 사카로미세스 카를스베르겐시스(Saccharomyces carlsbergensis), 지고사카로미세스 마조르(Zygosaccharomyces major), 사카로미세스 락틱(Saccharomyces lactics), 사카로미세스 록시이(Saccharomyces rouxii), 및 한세뉼라 아노말라(Hansenula anomala)로 구성된 군에서 선택되는 것을 특징으로 한다.Yeast used for the culture is isolated from yeast, Saccharomyces ( Saccharomyces cerevisiae), as a Saccharomyces ellipsis Soi Deus (Saccharomyces ellipsoideus), Saccharomyces Korea Augustine (Saccharomyces coreanus), saccharose in MRS car's Bergen sheath (Saccharomyces carlsbergensis), as is Saccharomyces Mazu Le (Zygosaccharomyces major), in a MRS lactic (Saccharomyces lactics), Saccharomyces Saccharomyces roksiyi (Saccharomyces rouxii), and a century nyulra cyano dry ( Hansenula anomala ) is characterized in that it is selected from the group consisting of.
본 발명의 실시예에서 확인한 바와 같이, 분쇄된 도라지를 상기 효모를 이용하여 배양하는 경우, 플라티코딘 D의 함량이 효과적으로 증가됨을 확인하였다 (실시예 2 및 도 2 참조).
As confirmed in the embodiment of the present invention, when culturing the ground bellflower using the yeast, it was confirmed that the content of Platicodin D effectively increased (see Example 2 and Figure 2).
본 발명의 한 양태에 따르면, 본 발명은 상기 플라티코딘 D의 함량이 증가된 발효 도자리 제조방법 중 어느 하나의 제조방법에 따라 제조되는 것을 특징으로 하는 플라티코딘 D의 함량이 증가된 발효 도라지 조성물을 제공한다.According to an aspect of the present invention, the present invention is fermentation with an increase in the content of Platicodin D, characterized in that it is prepared according to any one of the manufacturing method of the fermentation dodo method with increased content of the Platicodin D It provides a bellflower composition.
플라티코딘 D는 도라지의 주요 약리성분을 가지는 사포닌으로써, 항세포사멸(anti-apoptosis), 항비만(anti-obesity) 및 항염증(anti-inflammation) 등의 효능이 탁월한 것으로 알려져 있으며, 약물학적 가치가 큰 단일성분으로 알려져 있다. 따라서 본 발명의 제조방법을 통해 플라티코딘 D의 함량이 증가된 발효 도라지 조성물은 기능성 식품 조성물 또는 약제학적 조성물에 유용하게 사용될 수 있을 것으로 사료된다.Platicodine D is a saponin with major pharmacological components of bellflower, and is known to be excellent in anti-apoptosis, anti-obesity and anti-inflammation. It is known as a valuable single component. Therefore, the fermented bellflower composition with increased content of Platicodin D through the preparation method of the present invention may be usefully used in functional food compositions or pharmaceutical compositions.
또한, 본 발명의 조성물은 도라지 고유의 쓴 맛 성분 분자를 포접하여 도라지의 고미(苦味)를 감소시키는 것을 특징으로 한다. In addition, the composition of the present invention is characterized in that it is possible to reduce the bitterness of the bellflower by enclosing the bellflower intrinsic bitter component molecule.
본 발명에 있어서 상기 포접은 실시예 1-4에서 제조된 발효 도라지 추출물을 알파, 베타, 감마 싸이클로 덱스트린 및 덱스트린으로 구성된 군에서 선택된 덱스트린과 교반하여 포접시킨 것을 특징으로 한다.In the present invention, the inclusion is characterized in that the fermented bellflower extract prepared in Examples 1-4 was included by stirring with dextrin selected from the group consisting of alpha, beta, gamma cyclodextrin and dextrin.
구체적으로, 발효시킨 도라지 추출액의 고형분 대비 1% 내지 40 w/w%의 알파, 베타, 감마 싸이클로 덱스트린 또는 덱스트린을 첨가하여 0.5 내지 5 시간 동안 50 내지 500 rpm의 조건으로 교반하여 포접 반응시키는 경우, 도라지 고유의 쓴 맛 성분 분자를 포접할 수 있으며, 이로인해 도라지 고유의 향미는 유지한 채 도라지의 쓴 맛 만을 제거하고, 이와 동시에 도라지 추출물의 용해도와 안정성을 높이고, 액상제형화시에 투명성을 높여 제품의 전반적인 품질을 향상시킬 수 있다.Specifically, when the addition of 1% to 40 w / w% of alpha, beta, gamma cyclodextrin or dextrin relative to the solid content of the fermented bellflower extract and stirred in a condition of 50 to 500 rpm for 0.5 to 5 hours, It can enclose the bellflower's unique bitter taste molecule, thereby removing only the bellflower's bitter taste while maintaining the bellflower's inherent flavor, and at the same time, increasing the solubility and stability of the bellflower extract and improving transparency during liquid formulation. It can improve the overall quality of the product.
본 발명에 있어서, 상기 조성물은 폐렴원인균에 대한 항균 효과를 갖는 것을 특징으로 한다.In the present invention, the composition is characterized in that it has an antimicrobial effect against pneumococcal bacteria.
상기 폐렴원인균은 폐렴간균인 Klebsiella pneumoniae인 것을 특징으로 한다.Klebsiella pneumoniae is the causative agent of Klebsiella pneumonia It is characterized by being pneumoniae .
본 발명의 구체적인 실시예에서, 폐렴 유발 세균인 K. pneumoniae에 대한 본 발명에 따른 발효 도라지의 항균 효과를 측정한 결과, 상기 균에 대한 항균력이 있음을 확인하였으며, 특히 발효시키지 않은 도라지 추출물에 비해 발효 도라지의 항균효과가 더 뛰어남을 확인하였다 (실시예 4 및 도 4 참조).
In a specific embodiment of the present invention, K. As a result of measuring the antimicrobial effect of the fermented bellflower according to the present invention against pneumoniae , it was confirmed that there is an antimicrobial activity against the bacterium, and in particular, it was confirmed that the antibacterial effect of the fermented bellflower was superior to the fermented bellflower extract (Example 4 and FIG. 4).
이상 설명한 바와 같이, 본 발명에 따르면 탁주 제조공정을 적용시킨 본 발명의 발효 도라지 제조방법을 이용하여, 플라티코딘 D의 함량이 증가된 발효 도라지를 제조할 수 있다.As described above, according to the present invention, by using the fermented bellflower production method of the present invention to which the Takju production process is applied, fermented bellflower with increased content of Platicodin D can be prepared.
본 발명의 실시예를 통해, 분쇄된 도라지를 누룩에서 분리한 효모로 배양하는 경우, 누룩으로 발효시키는 경우 또는 효모로 배양한 후 누룩으로 발효시키는 경우 일반 도라지 추출물에 비해 플라티코딘 D의 함량이 유의적으로 증가되는 것을 확인하였으며, 발효 도라지를 싸이클로 덱스트린 또는 덱스트린으로 포접시키는 경우 도라지 특유의 쓴 맛을 제거할 수 있었다. 따라서 본 발명의 제조방법을 통해 제조된 플라티코딘 D의 함량이 증가된 발효 도라지 조성물은 기능성 식품 조성물 또는 약제학적 조성물에 유용하게 사용될 수 있을 것으로 사료된다.
According to an embodiment of the present invention, when the cultivated crushed bellflower in yeast isolated from yeast, fermented with yeast or fermented with yeast after incubating with yeast, the content of Platicodin D is higher than that of general bellflower extract. It was confirmed that the increase significantly, and when the fermented bellflower is enclosed in the cyclodextrin or dextrin can be removed the bitter taste peculiar to the bellflower. Therefore, the fermented bellflower composition with increased content of Platicodin D prepared through the preparation method of the present invention may be usefully used in functional food compositions or pharmaceutical compositions.
도 1은 발효 도라지의 제조 모식도를 나타낸 것이다.
도 2는 각 제조 공정에 따라 제조된 발효 도라지의 플라티코딘 D 함량을 측정한 결과이다.
도 3은 발효 도라지(실시예 1-4의 시료)를 싸이클로 덱스트린 또는 덱스트린으로 포접시킴에 따른 고미의 변화를 측정한 결과이다.
도 4는 발효 도라지(실시예 1-4의 시료)의 항균효과를 측정한 결과이다.Figure 1 shows a schematic diagram of the production of fermented bellflower.
Figure 2 is the result of measuring the Platicodin D content of the fermented bellflower prepared according to each manufacturing process.
Figure 3 is the result of measuring the change in the taste of the fermented bellflower (sample of Example 1-4) by inclusion of the cyclodextrin or dextrin.
4 is a result of measuring the antibacterial effect of fermented bellflower (sample of Example 1-4).
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.
Hereinafter, the present invention will be described in more detail with reference to Examples. Since these examples are only for illustrating the present invention, the scope of the present invention is not to be construed as being limited by these examples.
실시예Example 1. 탁주 제조공정을 이용한 발효 도라지 제조 1. Fermented Bellflower Production Using Takju Production Process
1-1. 도라지 추출물 제조1-1. Bellflower extract manufacturer
도라지를 분쇄하고, 분쇄된 도라지 1.5 kg과 10 배 분량의 이온수 15 L를 발효조에 넣어 95 ℃, 3 시간의 조건으로 추출하였다. 이후 추출액을 여과한 후, 농축하여 동결건조 하였다.
The bellflower was pulverized, 1.5 kg of pulverized bellflower and 15 liters of 10-fold amount of ionized water were placed in a fermenter and extracted under the condition of 95 ° C. for 3 hours. The extract was then filtered, concentrated and lyophilized.
1-2. 누룩 발효한 발효 도라지 제조1-2. Yeast Fermented Bellflower Production
상기와 같이 도라지를 분쇄하고, 분쇄된 도라지 1.5 kg과 10 배 분량의 이온수 15 L를 발효조에 넣어 121 ℃에서 30 분간 멸균한 후, 30 ℃로 온도를 낮추었다. 이후 상기 발효조에서 멸균시킨 도라지 시료를 미리 분쇄해 놓은 누룩 100 g과 함께 배양기에 넣고 30 ℃에서 150 rpm으로 교반하면서 3 일 동안 배양하였다. 배양이 종료된 액을 여과 및 농축하여 동결건조 하였다.
The bellflower was pulverized as described above, and 1.5 kg of pulverized bellflower and 15 L of ionized water 15 L were put in a fermenter and sterilized at 121 ° C. for 30 minutes, and then the temperature was lowered to 30 ° C. Thereafter, the bellflower samples sterilized in the fermenter were put into an incubator with 100 g of pre-crushed Nuruk and incubated for 3 days while stirring at 30 rpm to 150 rpm. After the culture was completed, the solution was filtered and concentrated to lyophilize.
1-3. 효모 배양한 발효 도라지 제조1-3. Production of Fermented Bellflower Cultured in Yeast
상기와 같이 도라지를 분쇄하고, 분쇄된 도라지 1.5 kg과 10 배 분량의 이온수 15 L를 발효조에 넣어 121 ℃에서 30 분간 멸균한 후, 30 ℃로 온도를 낮추었다. 이후 상기 발효조에서 멸균시킨 도라지 시료에 YM 배지(Yeast Extract 3.0 g/L, Malt Extract 3.0 g/L, Peptone 5.0 g/L 및 Dectrose 10.0 g/L)에서 30 ℃, 1 일간 배양한 효모 종균액(누룩에서 분리한 Saccharomyces cerevisiae 균주) 300 mL을 접종한 후, 이를 배양기에 넣고 30 ℃에서 150 rpm으로 교반하면서 3일 동안 배양하였다. 배양이 종료된 액을 여과 및 농축하여 동결건조 하였다.
The bellflower was pulverized as described above, and 1.5 kg of pulverized bellflower and 15 L of ionized water 15 L were put in a fermenter and sterilized at 121 ° C. for 30 minutes, and then the temperature was lowered to 30 ° C. The yeast seed solution incubated for 1 day at 30 ℃ in YM medium (Yeast Extract 3.0 g / L, Malt Extract 3.0 g / L, Peptone 5.0 g / L and Dectrose 10.0 g / L) in the bellflower sterilized in the fermenter ( Saccharomyces Isolated from Yeast cerevisiae strain) was inoculated with 300 mL, and then put into the incubator and incubated for 3 days with stirring at 150 rpm at 30 ℃. After the culture was completed, the solution was filtered and concentrated to lyophilize.
1-4. 효모 배양 후, 누룩 연속 배양한 발효 도라지 제조1-4. Fermented Bellflower Production after Yeast Culture and Nuruk Continuous Culture
상기와 같이 도라지를 분쇄하고, 분쇄된 도라지 1.5 kg과 10 배 분량의 이온수 15 L를 발효조에 넣어 121 ℃에서 30 분간 멸균한 후, 30 ℃로 온도를 낮추었다. 이후 상기 발효조에서 멸균시킨 도라지 시료에 YM 배지에서 30 ℃, 1 일간 배양한 효모 종균액 300 mL을 접종한 후, 이를 배양기에 넣고 30 ℃에서 150 rpm으로 교반하면서 3일 동안 배양하였다. 배양 완료 후, 분쇄한 누룩을 상기 배양 시료에 첨가한 후, 30 ℃에서 3 일간 후숙성 배양하였다. 배양이 종료된 액을 여과 및 농축하여 동결건조 하였다.
The bellflower was pulverized as described above, and 1.5 kg of pulverized bellflower and 15 L of ionized water 15 L were put in a fermenter and sterilized at 121 ° C. for 30 minutes, and then the temperature was lowered to 30 ° C. After inoculating 300 mL of yeast seed solution incubated in YM medium at 30 ° C. for 1 day in a bellflower sample sterilized in the fermenter, it was added to the incubator and incubated for 3 days with stirring at 150 rpm at 30 ° C. After completion of the culture, crushed Nuruk was added to the culture sample, and then aged at 30 ° C for 3 days. After the culture was completed, the solution was filtered and concentrated to lyophilize.
실시예Example 2. 제조 공정에 따른 도라지 2. Bellflower according to the manufacturing process 발효물의Fermented 플라티코딘Platicodine D( D ( PlyticodinPlyticodin D) 함량 변화 측정 D) Content change measurement
상기 실시예 1에서 각각의 제조 공정에 따라 제조된 발효 도라지 분말에 함유된 플라티코딘 D 함량을 측정하기 위해, 액체 크로마토그래피(High Liquid Chromatography, HPLC, Waters)를 이용하였다. 각각의 발효 도라지 분말 1 g을 50 mL의 매스플라스크에 정량하여 넣은 후, 이온수로 용해하고, 0.45 mm membrane filter를 이용하여 여과하여 HPLC 시료로 사용하였다. HPLC 측정 시, 표준품으로는 플라티코딘 D를 각각 1 mg/mL의 농도로 메탄올에 녹여 스톡(stock) 용액으로 하여 1.0, 0.1 및 0.01 mg/mL의 검액을 제조하여 검략선용 표준용액으로 사용하여 검량선을 작성하였다. 이때 분석조건 및 이동상(mobile phase)의 조건은 하기 표 1에 나타내었다.
In order to measure the Platicodin D content contained in the fermented bellflower powder prepared according to the respective preparation processes in Example 1, liquid chromatography (High Liquid Chromatography, HPLC, Waters) was used. 1 g of each fermented bellflower powder was quantitatively placed in a 50 mL mass flask, dissolved in ionized water, filtered using a 0.45 mm membrane filter, and used as an HPLC sample. In the case of HPLC measurement, as standard, Platicodin D was dissolved in methanol at a concentration of 1 mg / mL, respectively, to prepare a stock solution of 1.0, 0.1, and 0.01 mg / mL as a stock solution. A calibration curve was prepared. The analysis conditions and mobile phase conditions are shown in Table 1 below.
[표 1. HPLC 분석 조건]Table 1. HPLC Analysis Conditions
HPLC 측정 결과, 도 2에 나타낸 바와 같이 누룩 또는 효모로 배양하지 않은 도라지 추출물(대조군)에 함유되어 있는 플라티코딘 D의 함량이 2.56 mg/g로 측정되었으며, 누락만을 접종하여 3 일간 후숙성(발효)시킨 발효 도라지는 4.33 mg/g으로 균주로 배양하지 않은 대조군 보다 약 1.5 배 정도 소폭 증가하였다. 또한 탁주에서 분리한 효모균으로 3 일간 발효시킨 발효 도라지의 플라티코딘 D 함량은 8.05 mg/g으로 균주로 배양하지 않은 발효물(대조군)보다 약 3 배 정도의 함량증가를 보였다. 그리고 탁주에서 분리한 효모균을 2일 배양한 후, 누룩을 첨가하여 3일 후숙성(발효)시킨 발효 도라지에서는 플라티코딘 D의 함량이 대조군에 비해 4.3 배 증가함을 확인하였다.
As a result of HPLC measurement, as shown in FIG. 2, the content of Platicodin D contained in the bellflower extract (control) not cultured with yeast or yeast was measured as 2.56 mg / g, and the omission was inoculated only for 3 days. Fermented bellflower, which had been fermented), increased slightly to 4.33 mg / g by 1.5 times than the control group which was not cultured with the strain. In addition, the content of Platicodin D in the fermented bellflower fermented with yeast isolated from Takju for 3 days was 8.05 mg / g, which was about three times higher than the fermented product (control). After 2 days of culturing yeast bacteria isolated from Takju, it was confirmed that the content of placodin D was increased 4.3 times compared to the control in the fermented bellflower fermented with fermentation (fermentation) for 3 days.
누룩은 Aspergillus oryzae와 Asp. niger mut. Kawachii 및 Asp. usami mut. Shirousamii 등을 비롯하여, 기타 약간의 Rhizopus , Mucor , Monascus등 속의 곰팡이와 Saccharomyces cereviase 형의 탁주효모와, 유산간균, 유산구균, Bacillus subtilis를 비롯한 통성혐기성의 Bacillus속균과 기타 구균등이 포함된 복합미생물체이다.Yeast are used in Aspergillus oryzae and Asp. niger mut. Kawachii and Asp. usami mut. Some other, including Shirousamii Fungi and Saccharomyces of the Genus Rhizopus , Mucor , Monascus Takju yeast of the cereviase type, lactobacillus, lactobacillus , Bacillus It is a complex microorganism containing subtilis , including anaerobic Bacillus spp. and other cocci.
누룩으로부터 순수 분리한 효모인 Saccharomyces cerevisiae 균주로 발효공정을 수행한 것과 누룩으로 발효공정을 수행한 것을 비교하였을 시, 플라티코딘 D의 함량이 증가한 것으로 보아 Saccharomyces serevisiae 단일균주가 누룩에 존재하는 복합균주보다 발효가 진행됨에 따라 플라티코딘 D의 생성률에 상대적으로 더 많은 영향을 미치는 것을 확인할 수 있으며, 이는 Saccharomyces serevisiae 균주가 증식하는데에 있어 복합균주에 존재하고 있는 저해균주에 의해 저해를 받는 것으로 사료된다. Saccharomyces, yeast pure from yeast When the fermentation process was performed with the cerevisiae strain and the fermentation process with the yeast, the content of placodin D was increased, indicating that the single strain of Saccharomyces serevisiae was more fermented as the fermentation proceeds than the complex strain in the yeast. It can be seen that it has a relatively more influence on the production rate of din D, which is Saccharomyces serevisiae It is considered that the strain is inhibited by the inhibiting strain present in the complex strain in the growth.
도라지를 1차적으로 단일 균주인 Saccharomyces serevisiae로 발효함으로써 활성화된 플라티코딘 D 생성능이 누룩에 존재하는 복합균주의 증가에 따라 2차적으로 플라티코딘 D의 생성능이 증가되었으며, 또한 이렇게 증가된 플라티코딘 D의 생성능은 복합균주가 생성한 여러 가지의 효소의 도움을 받아 생성능이 더욱 우수해진 것으로 사료된다.
The fermentation of Platycodon D production by fermenting the bellflower, Saccharomyces serevisiae primarily, increased the production of Platicodin D secondly with the increase of the complex strain present in the yeast. The production capacity of din D is thought to be better with the help of various enzymes produced by the complex strain.
실시예Example 3. 발효 도라지의 3. Fermented Bellflower 포접Enclosure 후 after 고미평가High evaluation
이후, 도라지의 쓴 맛을 제거하기 위해 발효 도라지 제조시 덱스트린 등으로 포접시켰다. 상기 포접 실험에 이용된 발효 도라지 시료는 플라티코딘 D의 생성률이 가장 많이 증가된 효모배양 후 누룩발효 시킨 시료(실시예 1-4)를 이용하였다.Thereafter, in order to remove the bitter taste of the bellflower, it was enclosed with dextrin or the like during fermented bellflower preparation. The fermented bellflower sample used in the inclusion experiment was a yeast fermentation sample (Example 1-4) after yeast culture in which the production rate of Platicodin D was most increased.
상기 실시예 1-4와 동일한 방법으로 도라지를 분쇄 및 멸균한 후, 효모배양 및 누룩발효가 종료된 액을 여과시킨 후, 농축시키면서 알파, 베타, 감마 싸이클로 덱스트린 또는 덱스트린을 고형분에 대해 약 10%를 첨가하고 30 분 동안 150 rpm으로 교반하여 포접 반응시킨 후 건조 하였다. 이후, 덱스트린의 포접이 발효 도라지의 고유 향미는 유지하면서 쓴 맛을 제거하는데 얼마나 효과가 있는지 측정하기 위해 관능평가를 수행하였다. 각각 5 ~ 30 %의 농도로 제조된 발효 도라지 포접 분말을 훈련된 5명의 관능검사요원을 대상으로 발효 도라지 포접 분말과 대조군(아무것도 첨가하지 않은 발효 도라지 농축액)을 기준으로 측정하였다. 이때, 대조군을 10의 수치로 정하고, 9단계 평점법으로 상대평가하여 이를 평균치 또는 평균치 ± 표준편차로 나타내었으며, 3회 이상 반복 분석하여, 던칸의 다중범위 검증법으로 유의성을 검증하였다.After pulverizing and sterilizing bellflower in the same manner as in Example 1-4, after the culture of yeast culture and yeast fermentation was filtered, the concentration of alpha, beta, gamma cyclodextrin or dextrin was about 10% based on the solid content. It was added and stirred at 150 rpm for 30 minutes to make a clathrate reaction and dried. Thereafter, sensory evaluation was performed to determine how effective the inclusion of dextrin was in removing the bitter taste while maintaining the inherent flavor of the fermented bellflower. Fermented bellflower clath powder prepared at a concentration of 5 to 30%, respectively, was measured based on the fermented bellflower clath powder and a control (fermented bellflower concentrate without adding anything) to five trained sensory inspectors. At this time, the control group was set to a value of 10, and was evaluated relative to the 9-step scoring method as an average value or an average value ± standard deviation, and repeated analysis three times or more, and verified the significance by Duncan's multi-range verification method.
관능평가 결과, 도 3에 나타낸 바와 같이 상기 여러 덱스트린으로 포접시킨 발효 도라지 중, 알파 또는 감마 싸이클로 덱스트린으로 포접시킨 경우, 발효 도라지의 고미가 현저히 감소함을 관찰하였다.
As a result of sensory evaluation, as shown in Figure 3, among the fermented bellflower clad with the various dextrins, it was observed that the delicacy of fermented bellflower was significantly reduced when the cladding with alpha or gamma cycle dextrin.
실시예Example 4. 4. 무발효No fermentation 및 발효 도라지 분말의 기관지 유발균에 대한 항균력 측정 Antimicrobial Activity of Bronchial Bacteria from Fermented Bellflower Powder
도라지로부터 유용물질을 분리하기 위해, 추출용매로 H2O를 사용하여 90 ℃, 3 시간의 조건으로 추출하고 동결건조를 실시하여 무발효 도라지 건조분말을 제조하였다. 또한, 발효 도라지 분말은 상기 효모 배양 후, 누룩 연속 배양한 도라지 발효물 제조방법과 동일한 방법으로 제조한 시료(실시예 1-4)를 이용하였다. 이후, 기관지 질환을 유발하는 세균에 대한 도라지의 항균효과를 알아보기 위해, K. pneumoniae 배양용 배지로 Nutrient agar를 제조한 후, 무발효 도라지 또는 발효 도라지 분말을 희석수와 혼합하여 각각 0.05, 0.5, 1, 3, 5%의 농도로 제조하였다. 상기 농도별로 제조한 각각의 무발효 및 발효 도라지 분말을 첨가한 배양액에 K. pneumoniae을 접종하여 37 ℃, 24 시간의 배양조건으로 배양하고, 배양완료 후 생균수 측정을 통하여 도라지 분말 처리에 따른 항균효과를 알아보았다.In order to separate the useful material from the bellflower, using a H 2 O as an extraction solvent extracted at 90 ℃, 3 hours and lyophilized to prepare a dry fermented bellflower powder. As the fermented bellflower powder, a sample prepared in the same manner as the method for preparing bellflower fermented product yeast was cultured after the yeast culture (Example 1-4) was used. Then, to determine the antimicrobial effect of bellflower on bacteria causing bronchial diseases, K. Nutrient agar was prepared as a culture medium for pneumoniae , and fermented bellflower or fermented bellflower powder was mixed with dilution water to prepare a concentration of 0.05, 0.5, 1, 3, and 5%, respectively. K to the culture medium to which each fermented and fermented bellflower powder prepared for each concentration was added. After inoculation with pneumoniae was incubated in the culture conditions of 37 ℃, 24 hours, and after the completion of the culture to determine the antimicrobial effect according to the treatment of bellflower powder.
기관지 질환 유발세균인 K. pneumoniae 에 대한 무발효 및 발효 도라지 추출분말의 항균효과를 측정한 결과, 도 4에 나타낸 바와 같이 발효 도라지 추출분말이 무발효 도라지 추출분말보다 뛰어난 항균력을 나타내었다. 특히, 발효 도라지 분말을 0.05% 농도로 첨가하는 경우 80% 이상의 억제작용을 보였으며, 5% 이상 첨가하는 경우에는 균의 증식이 일어나지 않아 100%의 억제작용을 나타내었다. 또한, 무발효 도라지도 0.5% 농도로 첨가하는 경우 60%의 억제작용을 나타내었으며, 3% 이상 첨가하는 경우에는 80% 이상의 억제작용을 나타내었다. 상기 결과를 통해, 기관지 질환 유발세균인 K. pneumoniae에 대한 도라지 추출분말의 항균활성은 무발효 도라지 및 발효 도라지 분말시료 속에 세균의 성장을 억제하는 약리성 유용물질들이 다수 포함되어 있기 때문인 것으로 사료되며, 발효를 진행하였을 시 더욱 약리성 유용물질들이 증가되어 탁월한 항균효과가 있는 것으로 확인되었다.Bronchial disease-causing bacterium K. As a result of measuring the antimicrobial effect of the non-fermented and fermented bellflower extract powder against pneumoniae , the fermented bellflower extract powder showed better antibacterial activity than the non-fermented bellflower extract powder as shown in FIG. In particular, when the fermented bellflower powder was added at a concentration of 0.05%, it showed an inhibitory effect of 80% or more, and when it was added 5% or more, the growth of the bacteria did not occur, indicating an inhibitory effect of 100%. In addition, the fermented Dorado also exhibited a 60% inhibitory effect when added at a concentration of 0.5%, and more than 80% when inhibited. Through the above results, bronchial disease-inducing bacteria K. The antimicrobial activity of the extracts of p . paniculata against pneumoniae may be due to the fact that the fermented bellflower and fermented bellflower powder samples contain a large number of pharmacologically useful substances that inhibit the growth of bacteria. It was found to have an excellent antibacterial effect.
Claims (14)
a) 도라지를 분쇄하는 단계;
b) 분쇄된 도라지를 멸균시키는 단계;
c) 멸균된 도라지를 누룩으로 발효시키는 단계;
d) 발효 완료된 도라지를 여과 및 농축시키는 단계; 및
e) 동결건조하여 분말화시키는 단계.
Fermented bellflower manufacturing method having an increased content of Platicodin D comprising the following steps:
a) grinding the bellflower;
b) sterilizing the ground bellflower;
c) fermenting the sterilized bellflower with yeast;
d) filtering and concentrating the fermented bellflower; And
e) lyophilization to powder.
According to claim 1, wherein 50 to 100 g of yeast per kg of the sterilized bellflower in step c) is added, and the content of Platicodin D is increased, which is incubated for 2 to 4 days at 25 to 35 ℃ Fermented Bellflower Production Method.
The method of claim 1, further comprising the step of incubating the sterilized bellflower with yeast before step c).
According to claim 3, wherein the yeast is isolated from yeast Saccharomyces ( Saccharomyces) cerevisiae), as a Saccharomyces ellipsis Soi Deus (Saccharomyces ellipsoideus), Saccharomyces Korea Augustine (Saccharomyces coreanus ), Saccharomyces carlsbergensis ), Zygosaccharomyces major ), Saccharomyces lactics ), Saccharomyces rouxii ), and Hansenula anomala ( Hensenula anomala ) is a method for producing a fermented bellflower with an increased content of Platicodin D, characterized in that selected from the group consisting of.
The method of claim 1, wherein the concentration of the step d), the method of producing a fermented bellflower with an increased content of Platicodin D, characterized in that it further comprises the step of inclusion.
[Claim 6] The method of claim 5, wherein the inclusion is alpha, beta, gamma cyclodextrin and dextrin selected from the group consisting of dextrin selected from the group consisting of fermented bellflower production method with an increased content of Platicodin D.
According to claim 5, The clathrate is 1 to 40 w / w% of dextrin to the solid content of fermented bellflower, and the content of Platicodin D is increased, characterized in that the stirring at 50 to 500 rpm for 0.5 to 5 hours Fermented bellflower manufacturing method.
a) 도라지를 분쇄하는 단계;
b) 분쇄된 도라지를 멸균시키는 단계;
c) 멸균된 도라지를 효모로 배양시키는 단계;
d) 발효 완료된 도라지를 여과 및 농축시키는 단계; 및
e) 동결건조하여 분말화시키는 단계.
Fermented bellflower manufacturing method having an increased content of Platicodin D comprising the following steps:
a) grinding the bellflower;
b) sterilizing the ground bellflower;
c) incubating the sterile bellflower with yeast;
d) filtering and concentrating the fermented bellflower; And
e) lyophilization to powder.
10. The method according to claim 8, inoculating 150 to 300 mL of the yeast seed solution per kg of the bellflower sterilized in step c), the content of the Platicodin D is characterized in that for 2 to 4 days incubation at 25 to 35 ℃ Increased fermented bellflower manufacturing method.
According to claim 8, wherein the yeast of step c) is isolated from yeast Saccharomyces cerevisiae ), Saccharomyces ellipsoideus ), Saccharomyces coreanus ), Saccharomyces carlsbergensis , Zygosaccharomyces major ), Saccharomyces lactics ), Saccharomyces rouxii ), and Hansenula anomala anomala ) fermented bellflower manufacturing method with increased content of Platicodin D, characterized in that selected from the group consisting of.
A fermented bellflower composition with increased content of Platicodin D, which is prepared according to any one of claims 1 to 8.
12. The fermented bellflower composition according to claim 11, wherein the composition is reduced by the inclusion of bellflower bitter component molecules.
The fermentation bellflower composition according to claim 12, wherein the inclusion of the fermented bellflower extract prepared according to the method of claim 1 is carried out by stirring with dextrin selected from the group consisting of alpha, beta, gamma cyclodextrin, and dextrin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110071878A KR101290795B1 (en) | 2011-07-20 | 2011-07-20 | Manufacturing methods of fermentation bellflower increased aneffective ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110071878A KR101290795B1 (en) | 2011-07-20 | 2011-07-20 | Manufacturing methods of fermentation bellflower increased aneffective ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130011013A KR20130011013A (en) | 2013-01-30 |
KR101290795B1 true KR101290795B1 (en) | 2013-07-29 |
Family
ID=47840058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110071878A KR101290795B1 (en) | 2011-07-20 | 2011-07-20 | Manufacturing methods of fermentation bellflower increased aneffective ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101290795B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105169345A (en) * | 2015-10-13 | 2015-12-23 | 青岛云天生物技术有限公司 | Traditional Chinese medicine composition for treating pneumococcal pneumonia and preparation method of traditional Chinese medicine composition |
KR101696399B1 (en) | 2016-07-19 | 2017-01-16 | 주식회사 성일푸드 | Method for fermenting ripening object using rice straws and method for manufacturing black ballon flower roots tea using the same |
KR20210026739A (en) | 2019-09-02 | 2021-03-10 | 한도라지영농조합법인 | Method for preparing bellflower root powder containing bellflower root extract as active ingredient |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102121937B1 (en) * | 2018-11-26 | 2020-06-11 | 대한민국 | Method for increasing platycodin D content in Platycodon grandiflorum |
KR102255666B1 (en) * | 2018-12-14 | 2021-05-25 | 대한민국 | Method for increasing platycodin D content in Platycodon grandiflorum using Weissella cibaria JW15 strain |
KR102595524B1 (en) * | 2023-08-07 | 2023-10-30 | 주식회사 그레잇풀 | Platycodon grandiflorum fermented product comprising platycodon grandiflorum and rice grain syrup and method for preparing thereof |
KR102652207B1 (en) * | 2023-08-25 | 2024-04-01 | 주식회사 큰마당 | Method for producing a fermented product in which the contents of saponin and compound K are changed by fermentation of bellflower concentrate, and a composition containing the fermented product produced through the method |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100640246B1 (en) | 2004-12-27 | 2006-11-01 | 정경식 | Fermented product, new compound obtained therefrom, and skin whitening products containing the same |
KR20090123458A (en) * | 2008-05-28 | 2009-12-02 | 주식회사 엘씨에스바이오텍 | A method for fermentation of natural plants or herbal medicines, a fermented product prepared therefrom and a cosmetic composition, a food composition and a pharmaceutical composition comprising the same |
KR100962587B1 (en) * | 2007-10-02 | 2010-06-11 | 동국대학교 산학협력단 | A method for fermentation of natural plants and herbal medicines, a fermented product prepared therefrom and a paharmaceutical composition, a cosmetic compositon and a food composition comprising the product |
KR20100066784A (en) * | 2008-12-10 | 2010-06-18 | (주)아모레퍼시픽 | Cosmetic composition for controlling anti-acne and anti-comed |
-
2011
- 2011-07-20 KR KR1020110071878A patent/KR101290795B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100640246B1 (en) | 2004-12-27 | 2006-11-01 | 정경식 | Fermented product, new compound obtained therefrom, and skin whitening products containing the same |
KR100962587B1 (en) * | 2007-10-02 | 2010-06-11 | 동국대학교 산학협력단 | A method for fermentation of natural plants and herbal medicines, a fermented product prepared therefrom and a paharmaceutical composition, a cosmetic compositon and a food composition comprising the product |
KR20090123458A (en) * | 2008-05-28 | 2009-12-02 | 주식회사 엘씨에스바이오텍 | A method for fermentation of natural plants or herbal medicines, a fermented product prepared therefrom and a cosmetic composition, a food composition and a pharmaceutical composition comprising the same |
KR20100066784A (en) * | 2008-12-10 | 2010-06-18 | (주)아모레퍼시픽 | Cosmetic composition for controlling anti-acne and anti-comed |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105169345A (en) * | 2015-10-13 | 2015-12-23 | 青岛云天生物技术有限公司 | Traditional Chinese medicine composition for treating pneumococcal pneumonia and preparation method of traditional Chinese medicine composition |
KR101696399B1 (en) | 2016-07-19 | 2017-01-16 | 주식회사 성일푸드 | Method for fermenting ripening object using rice straws and method for manufacturing black ballon flower roots tea using the same |
KR20210026739A (en) | 2019-09-02 | 2021-03-10 | 한도라지영농조합법인 | Method for preparing bellflower root powder containing bellflower root extract as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
KR20130011013A (en) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101290795B1 (en) | Manufacturing methods of fermentation bellflower increased aneffective ingredient | |
KR101753077B1 (en) | A method for preparing fermented ginseng extract and compositions comprising thereof | |
KR101370386B1 (en) | Preparation method of fermented red ginseng using effective micro-organisms | |
KR100881634B1 (en) | The manufacturing process of extrusion puffed, supersonics waves and fermented red ginseng and mountain ginseng extracts | |
KR101823585B1 (en) | Methods for preparing fermented ginseng extracts | |
KR101331171B1 (en) | Fermented-red gingseng or fermented-gingseng containing increased gensenoside rd and methods for preparation of the same | |
KR100824285B1 (en) | Processes for preparing a saccharified ginseng and ginseng extracts | |
KR101201197B1 (en) | Making method of ginseng liquor using ginseng fermentation which were made by microorganism for ginseng fermentation | |
KR20150050726A (en) | fermented red ginseng concentrate having hepatoprotective activity and manufacturing method thereof | |
CN112691125B (en) | Pharmaceutical composition for whitening or resisting aging, preparation method thereof and skin care product | |
KR0163239B1 (en) | Method for preparing ginseng fermented liquor by using the yeast | |
CN116948887A (en) | Bifidobacterium animalis CCFM1274 capable of converting ginsenoside and glycyrrhizic acid | |
KR20090041083A (en) | A manufacturing method of green tea vinegar | |
KR101404915B1 (en) | Mixed fermantation formulation for conversing saponins in ginsaeng and red ginsaeng and manufacturing method of fermented extract of ginsaeng or red ginsaeng and fermented extract of ginsaeng or red ginsaeng using the same | |
CN113502230B (en) | Hericium erinaceus strain and culture method thereof, hericium erinaceus-ginseng bidirectional solid fermentation method and method for efficiently converting rare ginsenoside | |
CN111485012A (en) | Method for preparing glycyrrhetinic acid monoglucuronide by liquorice fermentation | |
CN116103161A (en) | Plant endophytic fungus for producing eupatorium and application thereof | |
KR101970320B1 (en) | Composition for preventing, improving or treating respiratory diseases comprising fermented solution of Chaenomeles sinensis as effective component and production method thereof | |
CN117866850B (en) | Lactobacillus plantarum and application thereof in platycodon grandiflorum fermentation | |
KR102668792B1 (en) | Health functional food and pharmaceutical composition to help improve sleep quality | |
CN117547572B (en) | Preparation method, product and application of composite lactobacillus fermentation product of composition | |
CN116832073B (en) | Preparation method of pseudo-ginseng flower extract | |
CN114875104B (en) | Mulberry leaf ferment stock solution and preparation method and application thereof | |
CN111631393B (en) | Probiotic fermented product containing turnip and application thereof | |
CN109350648B (en) | Forsythia suspensa fermentation stock solution and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160705 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170704 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180702 Year of fee payment: 6 |